The Company affirms that it has no plans for a public or private offering at this time. Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash ...

Hoth Therapeutics (NASDAQ:HOTH) shares rose by a staggering 215% today following significant breakthrough in cancer treatment. Their Phase 2a clinical trial of Hoth's topical gel HT-001 has shown ...

Shares of Hoth Therapeutics HOTH skyrocketed 178.2% on Tuesday after the company announced positive interim safety and efficacy results from a mid-stage study of its lead candidate, HT-001 ...

Robb Knie, CEO of Hoth Therapeutics, remarked, "These results are a significant milestone, underscoring HT-001's potential to transform patient care by mitigating debilitating skin toxicities ...

Hoth Therapeutics (HOTH) shared encouraging interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address skin toxicities linked to Epidermal Growth Factor ...

Shares of Hoth Therapeutics rebounded after the company said it has no plans for a public or private offering at this time. Hoth stock was recently up 4.6%, at $2.38, in midday trading Wednesday ...

NEW YORK, Dec. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies, today announced that it has entered into an ...

Hoth Therapeutics' shares surged more than 250% to $3 following positive interim results from its Phase 2a trial of HT-001, aimed at treating skin toxicities from EGFR inhibitors in cancer ...

Hoth Therapeutics (NASDAQ:HOTH) has entered into an exclusive licensing agreement to develop potential anti-obesity treatments based on technology co-developed by Emory University and the U.S ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

1 Day HOTH 178.18% DJIA -0.42% Russell 2K -0.74% Health Care/Life Sciences -0.67% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent ...